These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25265895)

  • 1. Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.
    Norris V; Ambery C
    Drugs R D; 2014 Dec; 14(4):241-51. PubMed ID: 25265895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers.
    Norris V; Ambery C; Riley T
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):305-13. PubMed ID: 27128837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
    Bateman ED; Kornmann O; Ambery C; Norris V
    Pulm Pharmacol Ther; 2013 Oct; 26(5):581-7. PubMed ID: 23538170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
    Norris V; Ambery C
    Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.
    Ambery C; Riddell K; Daley-Yates P
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):399-407. PubMed ID: 27170445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
    Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
    Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
    Balaguer V; Albayaty M; Jimenez E; Wählby-Hamrén U; Astbury C; Seoane B; Malice MP; Lei A; Aggarwal A; Psallidas I
    Respir Res; 2020 Sep; 21(Suppl 1):212. PubMed ID: 32907575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of efficacy and safety of budesonide delivered via two dry powder inhalers.
    Kerwin EM; Pearlman DS; de Guia T; Carlsson LG; Gillen M; Uryniak T; Simonson SG
    Curr Med Res Opin; 2008 May; 24(5):1497-510. PubMed ID: 18419878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial.
    Ambery CL; Wielders P; Ludwig-Sengpiel A; Chan R; Riley JH
    Drugs R D; 2015 Sep; 15(3):281-91. PubMed ID: 26286203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
    Singh D; Balaguer V; Astbury C; Wählby-Hamrén U; Jimenez E; Seoane B; Villarroel C; Lei A; Aggarwal A; Psallidas I
    Respir Res; 2020 Sep; 21(Suppl 1):102. PubMed ID: 32907566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.
    Drollmann A; Brown M; Sechaud R; Perry S; Hara H; Jones I; Febbraro S
    Int J Clin Pharmacol Ther; 2014 May; 52(5):369-80. PubMed ID: 24569129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
    Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
    BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.
    Hegde SS; Hughes AD; Chen Y; Steinfeld T; Jasper JR; Lee TW; McNamara A; Martin WJ; Pulido-Rios MT; Mammen M
    J Pharmacol Exp Ther; 2014 Oct; 351(1):190-9. PubMed ID: 25100753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
    Jimenez E; Astbury C; Albayaty M; Wählby-Hamrén U; Seoane B; Villarroel C; Pujol H; Bermejo MJ; Aggarwal A; Psallidas I
    Respir Res; 2020 Sep; 21(Suppl 1):211. PubMed ID: 32907576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.